Chemet Related Published Studies
Well-designed clinical trials related to Chemet (Succimer)
Efficacy of succimer chelation of mercury at background exposures in toddlers: a randomized trial. [2011.03]
Efficacy of succimer chelation of mercury at background exposures in toddlers: a
randomized trial. [2011]
Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead. [2007.05]
Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead. [2007.03.31]
Effect of succimer on growth of preschool children with moderate blood lead levels. [2004.02]
The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. [2001.05.10]
A comparison of two dosing regimens of succimer in children with chronic lead poisoning. [1999.02]
The effects of succimer on the absorption of lead in adults determined by using the stable isotope 204Pb. [1994.10]
Well-designed clinical trials possibly related to Chemet (Succimer)
The effect of vitamin A on renal damage following acute pyelonephritis in children. [2011.03]
Effect of percutaneous nephrolithotomy and tract dilatation methods on renal function: assessment by quantitative single-photon emission computed tomography of technetium-99m-dimercaptosuccinic acid uptake by the kidneys. [2010.09]
The Swedish reflux trial in children: IV. Renal damage. [2010.07]
The Swedish reflux trial in children: v. Bladder dysfunction. [2010.07]
The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. [2010.07]
Does background postnatal methyl mercury exposure in toddlers affect cognition and behavior? [2010.01]
Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. [2009.10.23]
Importance of methodology on (99m)technetium dimercapto-succinic acid scintigraphic image quality: imaging pilot study for RIVUR (Randomized Intervention for Children With Vesicoureteral Reflux) multicenter investigation. [2009.07]
Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. [2008.09]
Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. [2008.03]
The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. [2006.11.29]
The effect of chelation on blood pressure in lead-exposed children: a randomized study. [2006.04]
IQ and blood lead from 2 to 7 years of age: are the effects in older children the residual of high blood lead concentrations in 2-year-olds? [2005.05]
Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. [2004.10]
Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. [2004.07]
Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. [2003.06]
Imaging studies after a first febrile urinary tract infection in young children. [2003.01.16]
Do children with falling blood lead levels have improved cognition? [2002.10]
Treatment of children with acute pyelonephritis: a prospective randomized study. [2001.11]
Children with moderately elevated lead levels: is chelation with DMSA helpful? [1999.06]
[Comparative study on therapeutic effects of gandou tablet I and dimercaptosuccinate acid in treating Wilson disease] [1999.02]
Five-year study of medical or surgical treatment in children with severe vesico-ureteral reflux dimercaptosuccinic acid findings. International Reflux Study Group in Europe. [1998.09]
Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid. [1998.01]
Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. [1998]
Placebo response in environmental disease. Chelation therapy of patients with symptoms attributed to amalgam fillings. [1997.08]
[Clinical study of integrated traditional and Western medicine therapy on hepatolenticular degeneration] [1997.03]
Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. [1995.07]
Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites. [1995.01]
DMSA administration to patients with alleged mercury poisoning from dental amalgams: a placebo-controlled study. [1994.03]
Conceptual and practical advances in the measurement and clinical management of lead toxicity. [1993.06]
Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. [1988.10]
Other research related to Chemet (Succimer)
The impact of succimer chelation on blood cadmium in children with background
exposures: a randomized trial. [2013]
Therapeutic efficiency of succimer used with calcium and ascorbic acid in the treatment of mild lead-poisoning. [2011.01]
Efficacy of Succimer Chelation of Mercury at Background Exposures in Toddlers: A Randomized Trial. [2010.10.01]
A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. [2009.11]
Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. [2009.08]
[Effects of chelation therapy with succimer in young rabbits of moderate lead poisoning] [2009.01]
Succimer chelation normalizes reactivity to reward omission and errors in lead-exposed rats. [2007.03]
Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. [2007.02]
Changes in brain biogenic amines and haem biosynthesis and their response to combined administration of succimers and Centella asiatica in lead poisoned rats. [2006.04]
Succimer therapy for congenital lead poisoning from maternal petrol sniffing. [2006.01.16]
Toxicokinetics of mercury elimination by succimer in twin toddlers. [2005]
Cadmium induced testicular damage and its response to administration of succimer and diphenyl diselenide in mice. [2004.09.25]
Chronic arsenic poisoning in the rat: treatment with combined administration of succimers and an antioxidant. [2004.05]
Succimer treatment and calcium supplementation reduce tissue lead in suckling rats. [2004.03]
Reductions in blood lead overestimate reductions in brain lead following repeated succimer regimens in a rodent model of childhood lead exposure. [2004.03]
Lead induced oxidative stress and its recovery following co-administration of melatonin or N-acetylcysteine during chelation with succimer in male rats. [2004]
Succimer (meso-2,3-dimercaptosuccinic acid (DMSA)) treatment of Andean children with environmental lead exposure. [2003.04]
Lead induced oxidative damage and its response to combined administration of alpha-lipoic acid and succimers in rats. [2002.08.15]
Combined administration of oxalic acid, succimer and its analogue for the reversal of gallium arsenide-induced oxidative stress in rats. [2002.06]
The effects of succimer chelation therapy on auditory function in rhesus monkeys. [2001.11]
Succimer treatment during ongoing lead exposure reduces tissue lead in suckling rats. [2001.09]
The effects of elevated blood lead levels and succimer chelation therapy on physical growth in developing rhesus monkeys. [2001.09]
Succimer for treatment of lead toxicosis in two cats. [2001.06.15]
Oral succimer decreases the gastrointestinal absorption of lead in juvenile monkeys. [2001.06]
Succimer and the reduction of tissue lead in juvenile monkeys. [2000.08.01]
Succimer and the urinary excretion of essential elements in a primate model of childhood lead exposure. [2000.04]
Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. [1999.12.15]
Efficacy of succimer chelation for reducing brain Pb levels in a rodent model. [1998.08]
A report of pediatric SUCCIMER overdose. [1998.04]
The effect of succimer therapy in lead intoxication using postural balance as a measure: a case study in a nine year old child. [1998.02]
Use of orally administered succimer (meso-2,3-dimercaptosuccinic acid) for treatment of lead poisoning in dogs. [1996.02.01]
The treatment of lead poisoning from gunshot wounds with succimer (DMSA) [1994]
Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient. [1994]
Succimer: the first approved oral lead chelator. [1993.12]
Hemolytic anemia associated with lead poisoning from shotgun pellets and the response to Succimer treatment. [1993.12]
Succimer, an oral lead chelator. [1991.12]
Other possibly related research studies
[Ingested lead cartridges cause trouble] [2005.12.15]
Effectiveness of diuretic injection on the measurement of differential renal function using Tc-99m DMSA in patients with a dilated renal pelvis. [2005.11]
Evaluation of acute pyelonephritis with DMSA scans in children presenting after the age of 5 years. [2005.10]
Arsenic induced blood and brain oxidative stress and its response to some thiol chelators in rats. [2005.09.16]
Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma. [2005.06]
Efforts to control the errant products of a targeted in vivo generator. [2005.06.01]
Evaluation of the use of technetium Tc 99m diethylenetriamine pentaacetic acid and technetium Tc 99m dimercaptosuccinic acid for scintigraphic imaging of the kidneys in green iguanas (Iguana iguana). [2005.01]
Paper chromatographic and paper elettrophoretic study of the solution chemistry of Tc-99m-methylendiphosphonate and of Tc-99m-dimercaptosuccinate for improving the tumour-affinity of Tc-99m during scintigraphic imaging of cancer. [2004.09]
Lead-induced oxidative stress and hematological alterations and their response to combined administration of calcium disodium EDTA with a thiol chelator in rats. [2004]
99mTc ethylene dicysteine scintigraphy for diagnosing cortical defects in acute pyelonephritis: a comparative study with 99mTc dimercaptosuccinic acid. [2004.09]
Measurement of renal function by calculation of fractional uptake of technetium-99m dimercaptosuccinic acid. [2004]
Arsenic trioxide poisoning: a description of two acute overdoses. [2004.07]
Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury. [2004.08]
Power Doppler ultrasonography in the diagnosis of acute childhood pyelonephritis. [2004.09]
Technetium-99m-L,L-ethylenedicysteine renal scan as a single-modality investigation for the evaluation of renal morphology and function: a comparative study with technetium-99m-dimercaptosuccinic acid. [2004.07]
In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. [2004.10]
Combined administration of taurine and meso 2,3-dimercaptosuccinic acid in the treatment of chronic lead intoxication in rats. [2004.04]
Individual renal function based on 99mTc dimercaptosuccinic acid uptake corrected for renal size. [2004.02]
Therapeutic efficacy of lipoic acid in combination with dimercaptosuccinic acid against lead-induced renal tubular defects and on isolated brush-border enzyme activities. [2004.04.15]
Dimercaptosuccinic acid loading test for assessing mercury burden in healthy individuals. [2004.05]
Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial. [1999.08]
Combined early treatment with chelating agents DMSA and CaDTPA in acute oral cadmium exposure. [2004.03]
Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer. [2004]
Comparison of MRI and renal cortical scintigraphy findings in childhood acute pyelonephritis: preliminary experience. [2004.01]
DMSA study performed during febrile urinary tract infection: a predictor of patient outcome? [2004.06]
Therapeutic potential of monoisoamyl and monomethyl esters of meso 2,3-dimercaptosuccinic acid in gallium arsenide intoxicated rats. [2004.02.15]
|